Tandem Diabetes Care (TNDM) Projected to Post Quarterly Earnings on Wednesday

Tandem Diabetes Care (NASDAQ:TNDM) is anticipated to release its earnings data after the market closes on Wednesday, February 26th. Analysts expect Tandem Diabetes Care to post earnings of ($0.21) per share and revenue of $251.39 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Tandem Diabetes Care Price Performance

TNDM stock opened at $32.62 on Wednesday. The firm has a 50 day moving average of $35.63 and a 200-day moving average of $36.95. The company has a market cap of $2.14 billion, a price-to-earnings ratio of -16.90 and a beta of 1.32. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care has a 12-month low of $22.03 and a 12-month high of $53.69.

Analyst Ratings Changes

Several equities analysts recently issued reports on TNDM shares. Barclays lifted their price objective on Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. Citigroup decreased their price objective on shares of Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Canaccord Genuity Group dropped their target price on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Morgan Stanley raised shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price target on the stock in a report on Monday, December 2nd. Finally, Robert W. Baird lowered their price target on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating on the stock in a research report on Thursday, November 7th. Four equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Tandem Diabetes Care has an average rating of “Moderate Buy” and a consensus price target of $53.81.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.